Interpace Biosciences, Inc.
IDXG - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$33.01M
Close$
$-3.58
165.8% downside
Current Fair Value
165.8% downsideOvervalued by 165.8% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $33.01 Million |
|---|---|
| Enterprise Value | $31.30 Million |
| Earnings per Share | $27.75 |
| Beta | 0.63 |
| Outstanding Shares | 5,540,200 |
Return
| Return on Equity | 105.18% |
|---|---|
| Return on Assets | 70.76% |
| Return on Invested Capital | 11.17% |
Valuation & Multiples
| P/E Ratio | 0.21 |
|---|---|
| PEG | -0.17 |
| Price to Sales | 0.91 |
| Price to Book Ratio | 1.36 |
| Enterprise Value to Revenue | 0.87 |
| Enterprise Value to EBIT | 9.46 |
| Enterprise Value to Net Income | 1 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.04 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 12, 2026
EPS Estimate
$-0.48
Consensus analyst estimateRevenue Estimate
$11.10 M
Consensus analyst estimateNext Earnings Call
Expected Date
November 11, 2026
EPS Estimate
$-7.15
Consensus analyst estimateRevenue Estimate
$9.00 M
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Interpace Biosciences, Inc.
111 employees
CEO: Dr. Thomas W. Burnell Ph.D.
Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion ...